Kevin Craig, Chief Medical Officer of AtaiBeckley, discusses the current therapeutic landscape for major depressive disorder and therapeutic advances for this hard-to-treat disease.   Major depressive disorder (MDD), or depression, remains one of the most urgent and complex challenges in mental health. More than 300 million people1 worldwide live with the condition, but a substantial proportion of these people – commonly estimated at 30-502– do not respond to first-line treatments […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!